血清癌胚抗原在转移性肺腺癌患者冷冻治疗中的疗效评估及预后分析

目的探讨转移性肺腺癌患者冷冻治疗前后血清癌胚抗原（CEA）变化，及CEA在转移性肺腺癌患者预后中的意义。方法选择56例肺腺癌患者，47例接受肺内肿瘤的氩氦刀冷冻综合治疗，9例接受肺外肿瘤氩氦刀冷冻姑息治疗。检测患者冷冻治疗前后血清CEA水平，同时回访所有入组患者，统计患者总体生存期。结果59％转移性肺腺癌患者血清CEA水平在治疗前异常。综合治疗组冷冻术后血清CEA水平显著低于冷冻术前血清CEA水平（P=0．0033）。接受综合疗法的肺腺癌患者中，术前血清CEA水平正常患者的中位生存时间为26个月，术前血清CEA水平异常患者中位生存时间为12个月，术前血清CEA水平正常患者具有较长的总体生存期。结论对于转移性非小细胞肺腺癌冷冻治疗患者，血清CEA检测在患者治疗效果及预后评价上具有重要意义。

Evaluation of curative efficacy of serum carcinoma embryonic antigen in cryosurgery for metastatic lung adenocarcinoma and its the prognosis

Objective To evaluate the value of serum carcinoma embryonic antigen（CEA） levels in curative effect of cryoablation in metastatic lung adenocarcinoma patients. The prognosis of serum CEA levels in these patients was also assessed. Methods It was collected that the clinical data of 56 patients with metastatic lung adenocarcinoma who underwent comprehensive （47 patients with lung tumor cryoablation） or palliative （9 patients without lung tumor cryoablation） therapy. Pre-and post-cryoablation serum CEA levels were evaluated and overall survival were followed up in these patients. Results Serum CEA levels were different in 5% patients with metastatic lung adenocarcinoma compared with palliative treatment team, the serum CEA levels decreased significantly in comprehensive treatment team（ P = 0. 0033 ） ; In comprehensive treatment team, The median survival time was 26 months for patients with normal CEA expression level preoperatively. For patients with increased CEA expression level, The median survival time was 12 months. Patients with normal pre- treatment serum CEA levels can live longer（P = 0. 0023）. Conclusion Serum CEA can be used as a indicator to evaluate the therapeutic effects in cryoablation therapy of metastatic lung adenocarcinoma. Serum CEA level can also be used as a predictor of survival for these patients.